Wednesday, September 23, 2026

Collegium Pharmaceutical, Inc. And 2 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Collegium Pharmaceutical, Inc. And 2 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Collegium Pharmaceutical, Inc.

14.4% sales growth and 19.57% return on equity

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.

Collegium Pharmaceutical, Inc.'s sales growth this year is expected to be 9.5% and 10.8% for next year.

Year-on-year quarterly revenue growth grew by 2.8%, now sitting on 310.02M for the twelve trailing months.

Collegium Pharmaceutical, Inc.'s sales growth for the next quarter is 14.4%. The company's growth estimates for the present quarter and the next is 2900% and 60.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.57%.

Volatility

Collegium Pharmaceutical, Inc.'s last day, last week, and last month's current volatility was 0.43%, 0.97%, and 1.56%, respectively.

Collegium Pharmaceutical, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.31% (day), 4.87% (last week), and 4.44% (last month), respectively.

Collegium Pharmaceutical, Inc.'s Stock Yearly Top and Bottom Value

Collegium Pharmaceutical, Inc.'s stock is valued at $23.25 at 23:22 EST, way below its 52-week high of $26.91 and way higher than its 52-week low of $15.66.

Collegium Pharmaceutical, Inc.'s Moving Average

Collegium Pharmaceutical, Inc.'s worth is under its 50-day moving average of $23.88 and above its 200-day moving average of $21.80.

3. Invesco

20.2% sales growth and 5.43% return on equity

Invesco Ltd.

Invesco's sales growth this year is expected to be 11.6% and 5.9% for next year.

Year-on-year quarterly revenue growth declined by 6.5%, now sitting on 6.15B for the twelve trailing months.

Invesco's sales growth for the next quarter is 20.2%. The company's growth estimates for the present quarter and the next is 82.4% and 88.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.43%.

Volatility

Invesco's last day, last week, and last month's current volatility was 3.19%, 2.19%, and 1.77%, respectively.

Invesco's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.22% (day), 3.03% (last week), and 2.86% (last month), respectively.

Invesco's Stock Yearly Top and Bottom Value

Invesco's stock is valued at $26.53 at 23:22 EST, under its 52-week high of $26.90 and way higher than its 52-week low of $6.38.

Invesco's Moving Average

Invesco's worth is way above its 50-day moving average of $24.11 and way higher than its 200-day moving average of $18.34.

Previous days news about Invesco

Fidelity, invesco look to buy into India’s virus-led stock slump. According to Bloomberg Quint on Friday, 23 April, "While there's no denying that the outbreak and its financial and humanitarian implications remain the key focus for market watchers, some long-term investors from Fidelity International and Invesco are already seeking opportunities to add stocks. "

According to Bloomberg Quint on Friday, 23 April, "The $161 billion Invesco QQQ Trust Series 1 exchange-traded fund (ticker QQQ) has bled nearly $6 billion over the past five days in its worst stretch since the dot-com era of 2000, according to data compiled by Bloomberg. "

According to Bloomberg Quint on Monday, 26 April, "He suggested buying small-cap stocks, energy shares and the Invesco S&P 500 High Beta exchange-traded fund."

According to Bloomberg Quint on Monday, 26 April, "Investors pulled $8.7 billion from the $357 billion SPDR S&P 500 ETF Trust (ticker SPY) last week -- the most since September -- while the $164 billion Invesco QQQ Trust Series 1 (ticker QQQ) posted weekly outflows of $2.6 billion."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com